by Raynovich Rod | Feb 12, 2014 | Biopharmaceuticals
With Updates Today 2/13/14 XBI at $157.8 Biotechnology Bubblet- How High Can These Stocks Run? We reviewed mid-cap biopharmaceutical valuation in early October as part of our overall market model for a sector that defies classical analysis. Two emerging growth...
by Raynovich Rod | Feb 11, 2014 | 2024 Rayno Biopharmaceuticals Portfolio
Large Cap Biotechs Hover Near January 2014 Highs IBB At $254 on 2/11/14 The biotechnology sector has come roaring back after a 5-7% correction in February. Only one stock is at a new high Alexion (ALXN $171) . Many speculative mid and small caps are doing slightly...
by Raynovich Rod | Feb 9, 2014 | 2024 Rayno Biopharmaceuticals Portfolio
Life Science Stocks Surge Ahead From February Lows NASDAQ Up 1.67%, IBB Up 4%, FBIOX up 4.72%, XBI up 5.64%, XLV up 1.7% The soaring biotech sector would not let a losing week go by and took off early Friday erasing most losses for the week 2/3 to 2/7. Institutions...
by Raynovich Rod | Feb 5, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Biotech Bull Market Intact But Technicals Rule On January 27 we reiterated our model for life science stocks for 2014. We will review each component of our model and where the sector stands after about a 5% correction off highs with the sector still up 6% YTD...
by Raynovich Rod | Feb 3, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
But Momentum Is Easing As Investors Cash Out-IBB Is 5.5% Off Jan 22 Highs Caution Rules With Selling Pressure-Raise Cash to 15% January 2014 was up 12% which may be the best month ever in biotechnology at peak prices on January 22. But with the sector up over 62%...
by Raynovich Rod | Jan 30, 2014 | 2024 Rayno Biopharmaceuticals Portfolio, 2024 Rayno Tools and Diagnostics Portfolio
Update 12:40p NASDAQ Up 2% Cardiovascular Sciences (CSII $33.90) Up 15 %-Beats on Revenues and EPS. Q2 Revenues up 28% to $32.3M. Net Loss was $8.7M compared to $5.8M in 2013 fiscal Q2. Thermo Fisher (TMO $114) up 2.4% on 10% 2013 EPS gain. Q4 revenues up 6% to...
by Raynovich Rod | Jan 27, 2014 | Biopharmaceuticals
Follow Technical Levels -Avoid High Flyers Five Trends To Watch In Biotech-Preliminary Model Large Cap Biopharmaceuticals: metrics already reviewed-awaiting 2013 financial reporting. Key Technicals on Market indices: IBB,XBI,PBE, FBIOX, QQQ. Mid-Cap Emerging Growth in...
by Raynovich Rod | Jan 23, 2014 | Biopharmaceuticals
Update 1/24 With 2 hrs Trading to go…..Technical levels holding with sector up 7-8% YTD. NASDAQ still falling down 1.9% at 4139, QQQ down 1.5% Given the huge 11% move through the J.P.Morgan Conference in January we should only look at technical levels until...
by Raynovich Rod | Jan 23, 2014 | Biopharmaceuticals
Two Large Cap Pharmas Are Now Biotech Stocks: Abbvie, Inc. (ABBV) and Bristol -Myers Squibb (BMY) On our last post on the subject we postulated a model that the bull market in biotechnology would ride with the large cap leaders because they are perceived as growth...
by Raynovich Rod | Jan 21, 2014 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Moving Again-XBI up 1.54% After a 15%+ move January YTD you would think it is time to step back and take some off. Today the rally was in a full bull MOde with biopharmaceutical stocks leading the way. Here are big upside movers among our focus...